ITOLIZUMAB (monoclonal antybody)

Product Name: ITOLIZUMAB (monoclonal antybody)
CAS No.: 1116433-11-4
Chemical Name: ITOLIZUMAB (monoclonal antybody)
Synonyms: EQ-001;Itolizumab;Itolizumab (anti-CD6);Research Grade Itolizumab;ITOLIZUMAB (monoclonal antybody);Research Grade Itolizumab(DHD87601)
CBNumber: CB93110631
Formula Weight: 0
MOL File: Mol file

More

Less

ITOLIZUMAB (monoclonal antybody) Property

form: Liquid
color: Colorless to light yellow

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

ITOLIZUMAB (monoclonal antybody) Chemical Properties,Usage,Production

Uses

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19[1][2][3].

in vivo

Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD)^[7].

Animal Model:	Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)^[7]
Dosage:	60 μg or 300μg
Administration:	Intraperitoneal injection (i.p.), prior to PBMC transplantation.
Result:	Decreased mortality compared to the vehicle (100% vs. 10%).

References

[1] Saavedra D, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020 Nov 14;17(1):34. DOI:10.1186/s12979-020-00207-8
[2] Loganathan S, et al. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031. DOI:10.1080/14712598.2020.1798399
[3] Srivastava A. Itolizumab in Psoriasis. Indian J Dermatol. 2017 Jul-Aug;62(4):418-421. DOI:10.4103/ijd.IJD_467_16
[4] Freitas RF, et al. Modulation of CD4 T cell function via CD6-targeting. EBioMedicine. 2019 Sep;47:427-435. DOI:10.1016/j.ebiom.2019.08.008
[5] Globig AM, et al. High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature. Nat Commun. 2022 Jun 27;13(1):3688. DOI:10.1038/s41467-022-31229-z
[6] Bughani U, et al. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One. 2017 Jul 3;12(7):e0180088. DOI:10.1371/journal.pone.0180088
[7] Cherie Tracy Ng, et al. Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. Blood (2019) 134 (Supplement_1): 5603.

ITOLIZUMAB (monoclonal antybody) Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

ITOLIZUMAB (monoclonal antybody) Suppliers

China 23 United States 1 Global 24

Shanghai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847; 18021002903
Fax: QQ:3008007432
Email: 3008007409@qq.com
Country: China
ProdList: 71826
Advantage: 60

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8000
Advantage: 62

Guangzhou Hongyuan Chemical Co.,Ltd

Tel: 15817493340
Email: 981810490@qq.com
Country: China
ProdList: 1566
Advantage: 58

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10308
Advantage: 58

Bide Pharmatech Ltd.

Tel: 400-1647117 13681763483
Email: product02@bidepharm.com
Country: China
ProdList: 59936
Advantage: 58

TargetMol Chemicals Inc.

Tel: 4008200310
Email: marketing@tsbiochem.com
Country: China
ProdList: 24961
Advantage: 58

Biolab Reagents

Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Country: China
ProdList: 9868
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 6762
Advantage: 58

Shanghai Yifei Biotechnology Co. , Ltd.

Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Country: China
ProdList: 11973
Advantage: 58

Shanghai Aladdin Biochemical Technology Co.,Ltd.

Tel: 400-6206333 13167063860
Email: anhua.mao@aladdin-e.com
Country: China
ProdList: 48457
Advantage: 58

Changsha Fuzhen Biotechnology Co.，LTD

Tel: 0731-13823398 15111215862
Email: 313359644@qq.com
Country: China
ProdList: 4161
Advantage: 58

Wanxin Biotechnology (Jiaxing) Co., LTD

Tel: 0573-83568680 18057391398
Email: 3956524501@qq.com
Country: China
ProdList: 1442
Advantage: 58

Atagenix Laboratories

Tel: 027-87008169 17762441161
Email: info@atagenix.com
Country: China
ProdList: 10001
Advantage: 58

Sangon Biotech (Shanghai) Co.,Ltd.

Tel: 400-821-026
Email: Sales@sangon.com
Country: China
ProdList: 6710
Advantage: 58

AntibodySystem Laboratories SAS

Tel: 33175446423
Email: support@antibodysystem.com
Country: China
ProdList: 6739
Advantage: 58

Biosynth Biological Technology (Suzhou) Co Ltd

Tel: 51288865780
Email: sales@biosynth.com
Country: China
ProdList: 6051
Advantage: 58

Selleck Chemicals

Tel: 400-668-6834
Email: info@selleck.cn
Country: China
ProdList: 6071
Advantage: 58

Cell Sciences

Tel: 9785721070
Email: info@cellsciences.com
Country: China
ProdList: 6308
Advantage: 58

Guangzhou Zhuanyan Biotechnology Co., Ltd.

Tel: 18926165828
Country: CHINA
ProdList: 198
Advantage: 58

Guangzhou Weisheng Biotechnology Co., Ltd.

Tel: 17765667235
Country: CHINA
ProdList: 129
Advantage: 58

Guangzhou Chuangze Biotechnology Co., Ltd.

Tel: 18312220236
Country: CHINA
ProdList: 178
Advantage: 58

Biorbyt Ltd.

Tel: --
Fax: --
Email: info@biorbyt.com
Country: CHINA
ProdList: 6482
Advantage: 58

Proteintech China

Tel: --
Fax: --
Email: Proteintech-CN@ptglab.com
Country: CHINA
ProdList: 6290
Advantage: 58

1116433-11-4, ITOLIZUMAB (monoclonal antybody)Related Search:

Netakimab Sifalimumab VEGFR2 Kinase Inhibitor I Racotumomab Fletikumab Landogrozumab Blosozumab Alirocumab Romosozumab Ozanezumab

ITOLIZUMAB (monoclonal antybody)

Itolizumab

Research Grade Itolizumab(DHD87601)

Itolizumab (anti-CD6)

EQ-001

Research Grade Itolizumab

1116433-11-4